Raziel Therapeutics is developing RZL-012, a proprietary new chemical entity intended as a single-injection treatment into subcutaneous fat for submental fat reduction and fat disorders such as Dercum’s disease. The company is clinical-stage and recently secured financing to advance development. It raised $22m in a Series C financing to support Phase 2b development of RZL-012 for submental fat reduction and Dercum’s disease. Raziel received FDA orphan drug designation for RZL-012 for Dercum’s disease on November 19 and plans to initiate a Phase 2b Dercum’s study in Q2 2020. If the Phase 2b study is successful, the company could pursue an NDA filing as soon as 2021. Leadership includes CEO Alon Bloomenfeld and newly appointed Chairman Philippe Schaison.

Total raised

$22M

Funding rounds

1

Latest round

Series C

Latest activity

Dec 2019